A win for Teva in D. Delaware in carvedilol case

A post at biopharmadive.com highlighted some good news for Teva from a decision by Judge Stark in D. Delaware related to the generic drug carvedilol. Of note was text about an expert witness for plaintiff GSK:


GSK even provided an expert, a physician named Peter McCullough, to show Teva induced at least one doctor to prescribe generic carvedilol.

But one big problem, as Stark noted, was that McCullough didn't read the generic's label.

"As Dr. McCullough concedes that he did not read Teva's label, he cannot state, for instance, that he noticed or otherwise knew what (if anything) that label said about using carvedilol to treat CHF."



Toward the end of the post was a reference to Teva's MS drug Copaxone:



Yet Stark's ruling is surely a welcome reprieve for Teva, which is facing serious problems, including an enormous debt load and looming competition to its blockbuster multiple sclerosis drug Copaxone (glatiramer acetate).



To be clear, there is more than "looming" competition. A generic version of Teva's 40 mg Copaxone formulation was launched in October 2017. [The famous Supreme Court case related to the 20 mg formulation.]


Link to biopharmadive post:
https://www.biopharmadive.com/news/tevas-skinny-label-generic-didnt-cause-infringement-of-gsks-patent-ju/520283/


See also the May 2017 post on IPBiz:
The future of generic Copaxone?

AND

http://ipbiz.blogspot.com/2016/08/teva-loses-on-40mg-copaxone-for-ms-at.html